Masimo Corp. Stock
€154.85
Your prediction
Masimo Corp. Stock
Pros and Cons of Masimo Corp. in the next few years
Pros
Cons
Performance of Masimo Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Masimo Corp. | -1.530% | 0.748% | 3.199% | -0.290% | 39.254% | -5.348% | -22.010% |
| Bio-Rad Labs Inc. A | -0.660% | 2.341% | 0.460% | 6.278% | -6.786% | -44.455% | -50.535% |
| Haemonetics Corp. | 0.820% | -5.000% | -10.182% | - | -27.883% | - | - |
| CONMED Corp. | -1.960% | -5.063% | -23.077% | -44.954% | -14.286% | -68.085% | -72.973% |
Comments
News
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition
On February 17, 2026, Bridger Management disclosed in a Securities and Exchange Commission (SEC) filing that it sold out its entire position in Masimo (NASDAQ:MASI).
According to a Securities and
This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement
On February 17, 2026, Parkman Healthcare Partners disclosed a new position in Masimo Corporation (NASDAQ:MASI), acquiring 200,000 shares in the fourth quarter worth an estimated $26.01 million at
Naya Capital Adds Masimo Shares
According to an SEC filing dated Feb. 18, Naya Capital Management UK Ltd disclosed a new position in Masimo (NASDAQ:MASI), acquiring nearly 1.6 million shares.
Masimo is a leading provider of


